Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
12 nov. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Third Quarter 2024 Financial Results
and Business Updates
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
16 oct. 2024 09h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
19 sept. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
27 août 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus presents clinical data update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
08 août 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
26 juil. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
14 juin 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Three Clinical Data Updates on obe-cel at EHA
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
31 mai 2024 08h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
17 mai 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
02 avr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL